The 10 that are cited most themselves, of 11.
Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision
As regards the marketing authorisation of designated orphan medicinal products, Article 7 of Regulation No 141/2000 lays down the procedure to be followed and Article 8 thereof sets out the conditions attaching to the market exclusivity …
22 Jan 2015 · 62012TJ0140
Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision
Thirdly, should a competing undertaking obtain designation as an orphan medicinal product for a medicinal product similar to human fibrinogen, but having a significant benefit, it still has to obtain marketing authorisation for that …
9 Sep 2010 · 62007TJ0264
Judgment of the General Court (Second Chamber) of 5 December 2018. Bristol-Myers Squibb Pharma EEIG v European Commission and European MedicDecision
Similarly, with regard to the argument put forward by the applicant in the alternative that Empliciti (Elotuzumab) should not have been compared with the authorised medicinal product Kyprolis (Carfilzomib) after 3 July 2015, that is, after …
5 Dec 2018 · 62016TJ0329
Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision
In addition, it must be emphasised that Article 7(3) of Regulation No 141/2000 allows, specifically when an MA is granted for an orphan medicinal product, account to be taken of cases of partial overlap with MAs for other medicinal …
23 Sep 2020 · 62019TJ0549
Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision
16 May 2019 · 62017TJ0733
Order of the President of the General Court of 23 November 2018. GMP-Orphan (GMPO) v European Commission.Decision
It is apparent from the provisions of Regulation No 141/2000, and specifically from Article 5(1) and Article 7(3) thereof, that the procedure for the designation of a product as an orphan medicinal product has two separate stages, the …
23 Nov 2018 · 62017TO0733
Opinion of Advocate General Emiliou delivered on 11 July 2024. Mylan IRE Healthcare Ltd v European Commission.Decision
… Вж. също Известие на Комисията относно прилагането на членове 3, 5 и 7 от Регламент (ЕО) № 141/2000 за лекарствата сираци (ОВ C 424, 2016 г., стр. …
11 Jul 2024 · 62022CC0237
Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision
It is apparent from a reading of Article 5(12)(b) of Regulation No 141/2000 in conjunction with Article 7(3) of the regulation that at the time of the MA the COMP is to carry out a complete re-evaluation of the designation criteria in a …
24 Sep 2025 · 62022TJ0483
Act (EU) 2026/72Law
… е предназначен за покриване на специалните вноски, предвидени в член 7 от Регламент (ЕО) № 141/2000, различни от тези, предвидени в член …
Judgment of the Court (Eighth Chamber) of 4 October 2024. Mylan IRE Healthcare Ltd v European Commission.Decision
Освен това в своето Известие относно прилагането на членове 3, 5 и 7 от Регламент № 141/2000 за лекарствата сираци Комисията уточнява, …
4 Oct 2024 · 62022CJ0237